Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Nancy Lewis, MD
Novartis
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Novartis Investigative Site
North Sydney, New South Wales, Australia
- Novartis Investigative Site
Melbourne, Victoria, Australia
- Novartis Investigative Site
Toronto, Ontario, Canada
- Novartis Investigative Site
Essen, Germany
- Novartis Investigative Site
Chuo Ku, Tokyo, Japan
- Novartis Investigative Site
Amsterdam, Netherlands
- Novartis Investigative Site
L'Hospitalet de Llobregat, Catalonia, Spain
- Novartis Investigative Site
Zurich, Switzerland
- the Angeles Clinic and Research Institute
Los Angeles, California, United States
- Novartis Investigative Site
Chicago, Illinois, United States
- Md Anderson Cancer Center
Houston, Texas, United States
- Seattle Cancer Care Alliance
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 8 Sept 2017
- Primary completion
- 18 Dec 2020
- Completion
- 18 Dec 2020
- Last update posted
- 3 May 2022
- Registered enrollment
- 106
- Registry id
- NCT03172936
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.